CA2228298A1 - Non-ionic surfactant vesicles as therapeutic agent - Google Patents

Non-ionic surfactant vesicles as therapeutic agent Download PDF

Info

Publication number
CA2228298A1
CA2228298A1 CA002228298A CA2228298A CA2228298A1 CA 2228298 A1 CA2228298 A1 CA 2228298A1 CA 002228298 A CA002228298 A CA 002228298A CA 2228298 A CA2228298 A CA 2228298A CA 2228298 A1 CA2228298 A1 CA 2228298A1
Authority
CA
Canada
Prior art keywords
nisv
cytokines
lps
levels
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002228298A
Other languages
English (en)
French (fr)
Inventor
James Macdonald Brewer
James Alexander
Craig William Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protherics Medicines Development Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2228298A1 publication Critical patent/CA2228298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CA002228298A 1995-08-02 1996-08-01 Non-ionic surfactant vesicles as therapeutic agent Abandoned CA2228298A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515868.9A GB9515868D0 (en) 1995-08-02 1995-08-02 Therapeutic method
GB9515868.9 1995-08-02

Publications (1)

Publication Number Publication Date
CA2228298A1 true CA2228298A1 (en) 1997-02-13

Family

ID=10778664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002228298A Abandoned CA2228298A1 (en) 1995-08-02 1996-08-01 Non-ionic surfactant vesicles as therapeutic agent

Country Status (7)

Country Link
EP (1) EP0861074A1 (ja)
JP (1) JPH11510155A (ja)
AU (1) AU705662B2 (ja)
CA (1) CA2228298A1 (ja)
GB (1) GB9515868D0 (ja)
WO (1) WO1997004768A1 (ja)
ZA (1) ZA966603B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
JP4592347B2 (ja) * 2003-07-14 2010-12-01 株式会社ヤクルト本社 外用剤組成物
DE10358534A1 (de) 2003-12-13 2005-07-14 Henkel Kgaa Adhäsionshemmung von Mikroorganismen durch nichtionische Tenside
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MX359103B (es) * 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) * 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
GB201814959D0 (en) 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0374333A (ja) * 1989-08-11 1991-03-28 Nippon Oil & Fats Co Ltd ブレオマイシンの抗癌性増強方法
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines

Also Published As

Publication number Publication date
MX9800919A (es) 1998-10-31
AU6626296A (en) 1997-02-26
WO1997004768A1 (en) 1997-02-13
GB9515868D0 (en) 1995-10-04
ZA966603B (en) 1997-02-18
EP0861074A1 (en) 1998-09-02
AU705662B2 (en) 1999-05-27
JPH11510155A (ja) 1999-09-07

Similar Documents

Publication Publication Date Title
Broide et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
EP1031346B1 (en) Noninvasive vaccination through the skin
Da Silva et al. Therapeutic effect of oral Kalanchoe pinnata leaf extract in murine leishmaniasis
Badiee et al. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes
KR102176971B1 (ko) 관절염의 치료 방법
EP0722341B1 (en) Non-ionic surfarctant vesicles comprising antigens
AU705662B2 (en) Non-ionic surfactant vesicles as therapeutic agent
US5714141A (en) Use of interleukin 7 to enhance humoral immunity
JPH07505389A (ja) ワクチンにおける、または関する改良
JP2001500160A (ja) 蛋白・脂質小胞と当該小胞を含む自原性ワクチン
Kurup et al. Animal models of allergic bronchopulmonary aspergillosis
RODRIGUES Jr et al. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens
AU8010894A (en) Method of treating septic shock by preventing actin polymerization
KR19980701957A (ko) 신규 제약 조성물
MXPA98000919A (en) Non-ionic surfactant vessels as a therapist agent
Peeters et al. Therapeutic effect of chloroquine (CQ)-containing immunoliposomes in rats infected with Plasmodium berghei parasitized mouse red blood cells: comparison with combinations of antibodies and CQ or liposomal CQ
Lane et al. Cytokine production by cholesterol-loaded human peripheral monocyte-macrophages: the effect on fibrinogen mRNA levels in a hepatoma cell-line (HepG2)
Zhang et al. Anti-PD-1 antibody administration following hip fracture surgery reverses immune dysfunction and decreases susceptibility to infection
US6521263B1 (en) Immunomodulatory factors for immunosuppresant and antiallergic treatment
Dwivedi et al. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome
JP2024504263A (ja) 敗血症を治療するための薬物組成物及びその使用
CN107998116B (zh) 乙酰胺在抗银屑病药物中的应用
EP0335726A2 (en) Use of thymopentin and derivatives in treatment of HIV viremic patients
CN113041345A (zh) 一种纳米类毒素疫苗及其用途
US20170281714A1 (en) Method of treatment using liposomally formulated reduced glutathione to cooperate with il-10 to modulate inflammatory response triggered in hiv+ and tb immune-compromised diabetic patients

Legal Events

Date Code Title Description
FZDE Dead